TRUSELTIQ is a Oral Capsule in the Human Prescription Drug category. It is labeled and distributed by Qed Therapeutics, Inc.. The primary component is Infigratinib.
Product ID | 72730-101_0529ba94-9541-4ce3-8b59-0afb1e44e0f1 |
NDC | 72730-101 |
Product Type | Human Prescription Drug |
Proprietary Name | TRUSELTIQ |
Generic Name | Infigratinib |
Dosage Form | Capsule |
Route of Administration | ORAL |
Marketing Start Date | 2021-05-28 |
Marketing Category | NDA / |
Application Number | NDA214622 |
Labeler Name | QED Therapeutics, Inc. |
Substance Name | INFIGRATINIB |
Active Ingredient Strength | 125 mg/1 |
NDC Exclude Flag | N |
Listing Certified Through | 2023-12-31 |
Marketing Start Date | 2021-05-28 |
NDC Exclude Flag | N |
Sample Package? | N |
NDC | Brand Name | Generic Name |
---|---|---|
72730-101 | TRUSELTIQ | infigratinib |
72730-111 | TRUSELTIQ | infigratinib |
72730-202 | TRUSELTIQ | infigratinib |
72730-506 | TRUSELTIQ | infigratinib |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
TRUSELTIQ 90975538 not registered Live/Pending |
QED Therapeutics, Inc. 2020-10-19 |
TRUSELTIQ 90262906 not registered Live/Pending |
QED Therapeutics, Inc. 2020-10-19 |